Conference
Identifying variables that predict poor tumor biology and suboptimal outcomes in patients treated with cytoreduction and HIPEC.
Abstract
709
Background: Cytoreduction with HIPEC has improved survival in select group of patients with peritoneal carcinomatosis. Despite rigorous selection criteria, some patients invariably perform worse than others and are presumed to conceal poor tumor biology. Methods: A single institution analysis of all patients presenting with peritoneal carcinomatosis between 2003 and 2014. All patients who underwent CRS with HIPEC were …
Authors
Singla S; Francescutti V; Kane JM; Skitzki JJ
Volume
33
Pagination
pp. 709-709
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
January 20, 2015
DOI
10.1200/jco.2015.33.3_suppl.709
Conference proceedings
Journal of Clinical Oncology
Issue
3_suppl
ISSN
0732-183X